Executive Summary
Eventual FDA approval rates remain above 90% across most pathways — but first-cycle approval rates have been declining for a decade. Complete Response Letter (CRL) rates have risen from approximately 5% in 2015 to 21% in 2024. ANDA first-cycle approval sits at just 18.9%. Refuse-to-File rates have surged, and 84.5% of RTF letters cite scientific or technical deficiencies that could have been caught earlier.
The gap between eventual and first-cycle approval is where the industry's cost, time, and risk concentrate. Each rejected cycle means months of additional work, additional capital burn, and increased patient-access delay.
This paper analyzes the categories of deficiency driving first-cycle rejection — and the artifacts that, if drafted with greater precision and traceability, would close the gap.
Key Findings
- FDA CRL rates rose from approximately 5% in 2015 to 21% in 2024.
- ANDA first-cycle approval rates sit at just 18.9%.
- Refuse-to-File rates have surged across multiple FDA centers over the past 5 years.
- 84.5% of RTF letters cite scientific or technical deficiencies — issues that could be detected and resolved before submission.
- First-cycle deficiencies fall into three predictable categories: insufficient evidence, weak risk-benefit narrative, and inadequate cross-referencing between sections.
Read the full analysis
The full white paper — including methodology, source citations, and detailed analysis of each finding — is available as a downloadable PDF.